Patent · US Active

KRAS agonists, pharmaceutical compositions, and uses in managing cancer

US11648221B2 · kind B2 · utility

1Cited by
0References
8Claims
0Family size

Assignee

Inventor

Key dates

Filing dateSep 28, 2020
Grant dateMay 16, 2023
Priority date—
Expiry dateMay 6, 2041

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P35/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

In certain embodiments, this disclosure relates to KRAS agonists, pharmaceutical composition, and uses in managing cancer. In certain embodiments, the KRAS agonist is 4-(4-(2-bromoacetamido)butyl)benzoic acid, salt, prodrug, or derivative thereof. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering an effective amount of a compound of Formula I,

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.